[go: up one dir, main page]

SK286806B6 - Pyridazinónové zlúčeniny ako inhibítory cyklooxygenázy, farmaceutická kompozícia s ich obsahom a ich použitie - Google Patents

Pyridazinónové zlúčeniny ako inhibítory cyklooxygenázy, farmaceutická kompozícia s ich obsahom a ich použitie Download PDF

Info

Publication number
SK286806B6
SK286806B6 SK554-2001A SK5542001A SK286806B6 SK 286806 B6 SK286806 B6 SK 286806B6 SK 5542001 A SK5542001 A SK 5542001A SK 286806 B6 SK286806 B6 SK 286806B6
Authority
SK
Slovakia
Prior art keywords
phenyl
hydroxy
pyridazinone
methyl
propoxy
Prior art date
Application number
SK554-2001A
Other languages
English (en)
Slovak (sk)
Other versions
SK5542001A3 (en
Inventor
Lawrence A. Black
Anwer Basha
Michael E. Kort
Huaqing Liu
Catherine M. Mccarty
Meena V. Patel
Jeffrey J. Rohde
Michael J. Coghlan
Andrew O. Stewart
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Priority claimed from US09/427,768 external-priority patent/US6307047B1/en
Publication of SK5542001A3 publication Critical patent/SK5542001A3/sk
Publication of SK286806B6 publication Critical patent/SK286806B6/sk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SK554-2001A 1998-10-27 1999-10-27 Pyridazinónové zlúčeniny ako inhibítory cyklooxygenázy, farmaceutická kompozícia s ich obsahom a ich použitie SK286806B6 (sk)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US17960598A 1998-10-27 1998-10-27
US26187299A 1999-03-03 1999-03-03
US29849099A 1999-04-23 1999-04-23
US09/427,768 US6307047B1 (en) 1997-08-22 1999-10-27 Prostaglandin endoperoxide H synthase biosynthesis inhibitors
PCT/US1999/025234 WO2000024719A1 (fr) 1998-10-27 1999-10-27 Inhibiteurs de la biosynthese de la prostaglandine endoperoxyde h synthase

Publications (2)

Publication Number Publication Date
SK5542001A3 SK5542001A3 (en) 2001-12-03
SK286806B6 true SK286806B6 (sk) 2009-05-07

Family

ID=27497355

Family Applications (1)

Application Number Title Priority Date Filing Date
SK554-2001A SK286806B6 (sk) 1998-10-27 1999-10-27 Pyridazinónové zlúčeniny ako inhibítory cyklooxygenázy, farmaceutická kompozícia s ich obsahom a ich použitie

Country Status (19)

Country Link
EP (1) EP1124804B1 (fr)
JP (1) JP2003512292A (fr)
KR (1) KR100666838B1 (fr)
CN (1) CN1279026C (fr)
AT (1) ATE302759T1 (fr)
BG (1) BG65261B1 (fr)
BR (1) BR9914858A (fr)
CA (1) CA2347982A1 (fr)
CZ (1) CZ300570B6 (fr)
DE (1) DE69926903T2 (fr)
DK (1) DK1124804T3 (fr)
ES (1) ES2249919T3 (fr)
HK (1) HK1041876B (fr)
HU (1) HUP0105248A3 (fr)
NO (1) NO318623B1 (fr)
PL (1) PL198503B1 (fr)
SK (1) SK286806B6 (fr)
TR (1) TR200101765T2 (fr)
WO (1) WO2000024719A1 (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU738595B2 (en) 1997-11-19 2001-09-20 Kowa Co., Ltd. Novel pyridazine derivatives and medicines containing the same as effective ingredients
TWI241295B (en) 1998-03-02 2005-10-11 Kowa Co Pyridazine derivative and medicine containing the same as effect component
JP2000247959A (ja) 1999-02-26 2000-09-12 Kowa Co ピリダジン−3−オン誘導体及びこれを含有する医薬
PT1175214E (pt) 1999-12-08 2005-04-29 Pharmacia Corp Composicoes de inibidor de ciclo-oxigenase-2 com um inicio rapido do seu efito terapeutico
US6664256B1 (en) 2000-07-10 2003-12-16 Kowa Co., Ltd. Phenylpyridazine compounds and medicines containing the same
US6716829B2 (en) 2000-07-27 2004-04-06 Pharmacia Corporation Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders
MY131964A (en) 2000-09-15 2007-09-28 Pharmacia Corp 2-amino-2-alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors
AR031129A1 (es) 2000-09-15 2003-09-10 Pharmacia Corp Derivados de los acidos 2-amino-2-alquil-4-hexenoico y -hexinoico utiles como inhibidores de oxido nitrico sintetasa
US7012098B2 (en) 2001-03-23 2006-03-14 Pharmacia Corporation Inhibitors of inducible nitric oxide synthase for chemoprevention and treatment of cancers
DE10129320A1 (de) 2001-06-19 2003-04-10 Norbert Mueller Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen
EP1490064B1 (fr) 2002-02-14 2009-11-18 Pharmacia Corporation Pyridinones substitues comme modulateurs de la p38 map kinase
EP1572173B1 (fr) 2002-12-13 2010-04-28 Warner-Lambert Company LLC Ligand alpha-2-delta pour traiter des symptomes des voies urinaires inferieures
US20040204411A1 (en) * 2002-12-17 2004-10-14 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
ES2211344B1 (es) * 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
EP1604984A1 (fr) 2003-03-18 2005-12-14 Kowa Co., Ltd. Derive de phenylpyridazine soluble dans l'eau et medicament contenant ce derive
PL1534305T3 (pl) 2003-05-07 2007-03-30 Osteologix As Leczenie zaburzeń chrząstek i kości solami strontu rozpuszczalnymi w wodzie
ES2251866B1 (es) 2004-06-18 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
US7728031B2 (en) 2006-02-24 2010-06-01 Abbott Laboratories Octahydro-pyrrolo[3,4-b]pyrrole derivatives
EP1916240A1 (fr) * 2006-10-25 2008-04-30 Syngeta Participations AG Nouveaux derivés de pyridazine
CA2673545A1 (fr) 2006-12-22 2008-07-03 Recordati Ireland Limited Therapie combinee de troubles du tractus urinaire inferieur a l'aide de ligands de l'.alpha.2.delta. et d'ains
DE102007008840A1 (de) * 2007-02-23 2008-08-28 Bayer Healthcare Ag Neue polymorphe Form von 2-(4-Fluorophenyl)-4-3-hydroxy-3-methyl-1-butoxy)-5-[4-methylsulfonyl)phenyl]-3(2H)-pyridazinon (FHMP)
DE102007008839A1 (de) * 2007-02-23 2008-08-28 Bayer Healthcare Ag Verfahren zur Herstellung von 4-(3-Hydroxy-3-methyl-butoxy)-5-[4-(methylsulfonyl)phenyl]-2-arylpyridazin-3(2H)-onen
DE102007008843A1 (de) 2007-02-23 2008-08-28 Bayer Healthcare Ag Verfahren zur Herstellung von 4,5-Dihalogen-2-aryl-2H-pyridazin-3-onen
DE102007020689A1 (de) 2007-05-03 2008-11-06 Bayer Healthcare Ag Neue polymorphe Form von 2-(4-Fluorophenyl)-4-3-hydroxy-3-methyl-1-butoxy-5-[4-methylsulfonyl)phenyl]3/2H)-pyridazinon (FHMP)
DE102007020690A1 (de) * 2007-05-03 2008-11-06 Bayer Healthcare Ag Neue amorphe Form von 2-(4-Fluorophenyl)-4-3-hydroxy-3-mehtyl-1-butoxy)-6[4-methylsulfonyl)phenyl]-3(2H)-pyridazinon (FHMP)
DE102007025717A1 (de) * 2007-06-01 2008-12-11 Merck Patent Gmbh Arylether-pyridazinonderivate
GB0716414D0 (en) * 2007-08-22 2007-10-03 Syngenta Participations Ag Novel insecticides
EP2188288A1 (fr) 2007-09-11 2010-05-26 Abbott Laboratories N-oxydes d'octahydro-pyrrolo[3,4-b]pyrrole
GB0903493D0 (en) 2009-02-27 2009-04-08 Vantia Ltd New compounds
JP2012131708A (ja) * 2009-04-28 2012-07-12 Nissan Chem Ind Ltd 4位置換ピリダジノン化合物及びp2x7受容体阻害剤
FR2969606B1 (fr) * 2010-12-22 2013-01-11 Pf Medicament Derives de diarylpyridazinones, leur preparation et leur application en therapeutique humaine
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
JP7096598B2 (ja) 2016-09-07 2022-07-06 トラスティーズ オブ タフツ カレッジ イムノdash阻害剤及びpge2アンタゴニストを用いた併用療法
CN107334767B (zh) * 2017-06-08 2019-03-05 中国医学科学院医药生物技术研究所 一种哒嗪酮类化合物在肿瘤治疗中的应用
WO2021124344A1 (fr) * 2019-12-18 2021-06-24 Abida Dérivés de pyridazine et leur utilisation en tant qu'inhibiteurs de cyclooxygenase-2

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4238490A (en) * 1979-02-12 1980-12-09 Diamond Shamrock Corporation Antihypertensive pyridazin(2H)-3-ones
BR8108745A (pt) * 1980-08-07 1982-07-06 Diamond Shamrock Corp Difenilpiridazinonas herbicidas e reguladores do crescimento da planta
US5622948A (en) * 1994-12-01 1997-04-22 Syntex (U.S.A.) Inc. Pyrrole pyridazine and pyridazinone anti-inflammatory agents
AU6269496A (en) * 1995-06-12 1997-01-09 G.D. Searle & Co. Combination of a cyclooxygenase-2 inhibitor and a leukotrien e b4 receptor antagonist for the treatment of infla mmations
AU738727B2 (en) * 1997-03-14 2001-09-27 Merck Frosst Canada Ltd. Pyridazinones as inhibitors of cyclooxygenase-2
EP1007515A1 (fr) * 1997-08-22 2000-06-14 Abbott Laboratories Arylpyridazinones inhibitrices de la biosynthese de la prostaglandine endoperoxyde h synthase
AU741317B2 (en) * 1997-08-22 2001-11-29 Abbott Laboratories Arylpyridazinones as prostaglandin endoperoxide H synthase biosynthesis inhibitors
CA2294548A1 (fr) * 1997-08-22 1999-03-04 Abbott Laboratories Pyridazinones comme inhibiteurs de la biosynthese de la prostaglandine endoperoxyde h synthase

Also Published As

Publication number Publication date
EP1124804B1 (fr) 2005-08-24
HUP0105248A3 (en) 2002-09-30
ATE302759T1 (de) 2005-09-15
SK5542001A3 (en) 2001-12-03
KR100666838B1 (ko) 2007-01-11
NO20012061L (no) 2001-06-27
DK1124804T3 (da) 2005-12-12
HK1041876B (en) 2006-06-23
CN1342149A (zh) 2002-03-27
HK1041876A1 (en) 2002-07-26
CZ20011481A3 (cs) 2001-09-12
NO318623B1 (no) 2005-04-18
BG105523A (en) 2001-12-29
CA2347982A1 (fr) 2000-05-04
PL349256A1 (en) 2002-07-01
CZ300570B6 (cs) 2009-06-17
PL198503B1 (pl) 2008-06-30
DE69926903D1 (en) 2005-09-29
WO2000024719A1 (fr) 2000-05-04
EP1124804A1 (fr) 2001-08-22
HUP0105248A2 (hu) 2002-07-29
KR20010081101A (ko) 2001-08-27
DE69926903T2 (de) 2006-07-13
ES2249919T3 (es) 2006-04-01
TR200101765T2 (tr) 2002-02-21
BR9914858A (pt) 2002-02-05
CN1279026C (zh) 2006-10-11
NO20012061D0 (no) 2001-04-26
BG65261B1 (bg) 2007-10-31
JP2003512292A (ja) 2003-04-02

Similar Documents

Publication Publication Date Title
SK286806B6 (sk) Pyridazinónové zlúčeniny ako inhibítory cyklooxygenázy, farmaceutická kompozícia s ich obsahom a ich použitie
JP7754979B2 (ja) 疾患の治療に有用な複素環化合物
US7115591B2 (en) Prostaglandin endoperoxide H synthase biosynthesis inhibitors
EP1206474B1 (fr) Composes sulfonylphenylpyrazoles utiles en tant qu'inhibiteurs de cox-2
EP1246809B1 (fr) Composes de 5-aryl-1h-1,2,4-triazole en tant qu'inhibiteurs de cyclooxygenase-2 et compositions pharmaceutiques les contenant
EA021025B1 (ru) Соединения, эффективные в качестве ингибиторов ксантиноксидазы, способ их получения и содержащая их фармацевтическая композиция
JP2010532774A (ja) ピリミジニル−ピリダジノン誘導体
JPH11500748A (ja) Cox−2阻害剤のプロドラッグとしての3,4−ジアリール−2−ヒドロキシ−2,5−ジヒドロフラン
KR20180089569A (ko) 대사성 질환의 치료를 위한 ppar 절약형 티아졸리딘디온염
JP2001514669A (ja) シクロオキシゲナーゼ−2阻害薬としてのピリダジノン類
US6472416B1 (en) Sulfonylphenylpyrazole compounds useful as COX-2 inhibitors
JP4559849B2 (ja) 置換2−フェニル−3(2h)−ピリダジノン
CN103153991B (zh) 噻唑烷二酮化合物的合成方法
JP2002212179A (ja) 新規アニリド誘導体又はその塩及びこれを含有する医薬
CZ300847B6 (cs) Arylpyridazinony jako inhibitory biosyntézy prostaglandin endoperoxid H synthasy, jejich použití a farmaceutická kompozice s jejich obsahem
AU773237B2 (en) Prostaglandin endoperoxide H synthase biosynthesis inhibitors
MXPA01004247A (en) Prostaglandin endoperoxide h synthase biosynthesis inhibitors
HK1139652B (en) Biaryl ether urea compounds
HK1139652A1 (en) Biaryl ether urea compounds

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20101027